Cuba says second Covid vaccine Soberana 2 boasts 91.2% efficacy

Cuba said on Thursday that its two-shot Soberana 2 vaccine, delivered with a booster called Soberana Plus, had proven 91.2% effective in late stage clinical trials against the coronavirus, following similar news about its Abdala vaccine last month at 92.28% efficacy

The announcement came from state-run biopharmaceutical corporation BioCubaFarma, which oversees the Finlay Institute, the maker of Soberana 2, and the Center for Genetic Engineering and Biotechnology, the producer of Abdala.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)